Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Dapagliflozin

The first gliflozin (SGLT2 inhibitor) approved in Europe, in 2012, for type 2 diabetes. It removes excess glucose through the urine, independently of insulin. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.

Did you know?Born as a diabetes medicine, it has also shown benefits in heart failure and chronic kidney disease, even in people without diabetes.

DapagliflozinGo to the active ingredient →
DapagliflozinActive ingredientDapagliflozinCat. No. P-D014-001CAS 461432-26-8

EDQM standards 4

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.